List of insiders holdings for Entasis Therapeutics Holdings Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
Innoviva Inc. Innoviva Strategic Opportunities LLC 10% Owner | 2022-07-13 21:27:34 | 37,345,794 39,270,476 | 76,616,270 | Form 4 |
ASTRAZENECA PLC ASTRAZENECA AB 10% Owner | 2018-10-12 11:10:45 | 2,164,855 0 | 2,164,855 | Form 13D |
Blackstone Holdings II L.P. Blackstone Clarus III L.L.C. Blackstone Holdings I Blackstone Group L.P. Blackstone Group Management L.L.C. SCHWARZMAN STEPHEN A 10% Owner | 2019-01-15 09:25:30 | 0 1,623,405 | 1,623,405 | Form 3 |
Clarus Lifesciences III L.P. Clarus Ventures III GP L.P. Clarus Ventures III LLC Simon Nicholas LIPTAK ROBERT HENNER DENNIS Requadt Scott WHEELER KURT 10% Owner | 2020-07-09 16:48:59 | 1,339,836 0 | 1,339,836 | Form 13D |
Pivotal bioVenture Partners Fund I L.P. Pivotal bioVenture Partners Fund I G.P. L.P. Pivotal bioVenture Partners Fund I U.G.P. Ltd 10% Owner | 2018-12-21 21:10:34 | 1,180,178 0 | 1,180,178 | Form 13D |
Novo Holdings A/S 10% Owner | 2020-08-11 16:30:53 | 1,173,896 0 | 1,173,896 | Form 13G |
TPG Group Holdings (SBS) Advisors Inc. BONDERMAN DAVID COULTER JAMES G Former 10% Owner | 2018-10-09 17:05:57 | 1,020,748 0 | 1,020,748 | Form 13D |
Frazier Life Sciences VIII L.P. Topper James N FHM LIFE SCIENCES VIII L.P. FHM LIFE SCIENCES VIII L.L.C. Heron Patrick J 10% Owner | 2020-06-18 12:30:03 | 799,953 0 | 799,953 | Form 13D |
Gutch Michael See Remarks | 2022-02-15 16:05:08 | 75,404 0 | 75,404 | Form 4 |
Isaacs Robin Chief Medical Officer | 2019-01-22 17:00:11 | 56,500 0 | 56,500 | Form 4 |
Kimble Eric Wilson Chief Commercial Officer | 2020-01-27 16:06:33 | 50,000 0 | 50,000 | Form 4 |
GALAKATOS NICHOLAS Director | 2019-06-21 16:02:52 | 7,500 0 | 7,500 | Form 4 |
Preston Heather Director | 2019-06-21 16:03:07 | 7,500 0 | 7,500 | Form 4 |
Norden Gregory Director | 2019-06-21 16:03:52 | 7,500 0 | 7,500 | Form 4 |
HASTINGS DAVID C Director | 2022-07-11 16:05:27 | 0 0 | 0 | Form 4 |
Staples Andrew J. Director | 2018-09-25 20:50:56 | 0 0 | 0 | Form 3 |
Wagner Kristie Ann VP, Principal Fin & Acct Off | 2022-07-11 16:11:00 | 0 0 | 0 | Form 4 |
Triola Anna Diaz Chief Commercial Officer | 2022-07-11 16:10:15 | 0 0 | 0 | Form 4 |
Tommasi Ruben Chief Scientific Officer | 2022-07-11 16:09:41 | 0 0 | 0 | Form 4 |
Ronsheim Matthew Chief of Pharma Sciences & MFG | 2022-07-11 16:09:04 | 0 0 | 0 | Form 4 |
Perros Manoussos President and CEO | 2022-07-11 16:08:29 | 0 0 | 0 | Form 4 |
Mueller John Patrick Chief Development Officer | 2022-07-11 16:07:57 | 0 0 | 0 | Form 4 |
Meek David D. Director | 2022-07-11 16:07:22 | 0 0 | 0 | Form 4 |
Mayer Howard Director | 2022-07-11 16:06:51 | 0 0 | 0 | Form 4 |
Keiley Elizabeth M General Counsel | 2022-07-11 16:06:01 | 0 0 | 0 | Form 4 |
Berger Heather A. Director | 2022-07-11 16:04:56 | 0 0 | 0 | Form 4 |
Altarac David Chief Medical Officer | 2022-07-11 16:03:49 | 0 0 | 0 | Form 4 |
Sofinnova Venture Partners IX L.P. Sofinnova Management IX L.L.C. HEALY JAMES Mehra Anand POWELL MICHAEL 10% Owner | 2021-03-04 06:17:32 | 0 0 | 0 | Form 13D |